NCT02912949 2025-04-29A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)Partner Therapeutics, Inc.Phase 2 Active not recruiting250 enrolled 2 FDA